Biochemical Engineering Special Interest Group
biological engineering professionals
09 May 2017

Gammadelta Raises USD100m

Takeda Pharmaceutical Company and London-based venture capital firm Abingworth LLP are investing a combined $100 million into GammaDelta Therapeutics to develop that company’s T cell platform, which is based on the unique properties of gamma delta (yδ) T cells derived from human tissues. Under terms of the deal, Takeda will have the option to acquire GammaDelta should things work out favorably. Source: Biospace 9/5/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).